Metabolic changes in early neonatal life: NMR analysis of the neonatal metabolic profile to monitor postnatal metabolic adaptations

Georgakopoulou, Ioanna; Chasapi, Styliani A.; Bariamis, Steve E.; Varvarigou, Anastasia; Spraul, Manfred; Spyroulias, Georgios A.

doi:10.1007/s11306-020-01680-4

Cited by 11 publications

(20 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…37 Other work has used nuclear magnetic resonance (NMR)-based metabolomics of 253 healthy newborns to explore changes in the urinary metabolite profiles from the first and third days of life. 38 This work showed clear changes in the metabolite profiles with the first 72 h after birth and distinctions between late preterm and term newborn infants. 38 In a different NMR spectroscopy study of urinary metabolites, Diaz et al (2016) looked at prematurity in newborns.…”

Section: Ta B L E 1 (Continued)mentioning

confidence: 65%

“…38 This work showed clear changes in the metabolite profiles with the first 72 h after birth and distinctions between late preterm and term newborn infants. 38 In a different NMR spectroscopy study of urinary metabolites, Diaz et al (2016) looked at prematurity in newborns. 39 This study included 46 control infants with an average gestational age of 39 weeks and investigated the urine metabolomic profiles in comparison with 17 premature infants with an average gestational age of 35 weeks.…”

Section: Ta B L E 1 (Continued)mentioning

confidence: 65%

“…Other work has used nuclear magnetic resonance (NMR)‐based metabolomics of 253 healthy newborns to explore changes in the urinary metabolite profiles from the first and third days of life 38 38 . In a different NMR spectroscopy study of urinary metabolites, Diaz et al (2016) looked at prematurity in newborns 39 …”

Section: Metabolitesmentioning

confidence: 99%

See 2 more Smart Citations

Exploring functional metabolites in preterm infants

Renwick

Stewart

2021

Acta Paediatrica

View full text Add to dashboard Cite

Aim Metabolomics is the study of small molecules that represent the functional end points of cellular reactions that can impact health. Necrotising enterocolitis (NEC) and late onset sepsis (LOS) are the main cause of death in preterm infants surviving the initial days of life. Methods This review will explore and summarise the current literature exploring metabolomics in preterm infants. Results There are a relatively limited number of studies investigating metabolomics in preterm infants with NEC and/or LOS and matched controls. Nonetheless, it is evident across longitudinally age‐related metabolomic studies that there are significant changes in metabolite profiles post‐partum and over the first year of life. Existing studies have reported associations between the metabolite profiles of serum, urine and stool in health and disease in preterm infants. Although some studies have found selected metabolites are associated with disease, the specific metabolites vary from study to study, and larger studies are required. Excitingly, recent work has also begun to untangle how microbially produced metabolites can impact immunoregulation of the infant. Conclusion Metabolic exploration is an emerging research area with huge potential for developing novel biomarkers and better understanding disease processes in preterm infants.

show abstract

Section: Ta B L E 1 (Continued)mentioning

confidence: 65%

Section: Ta B L E 1 (Continued)mentioning

confidence: 65%

See 1 more Smart Citation

Exploring functional metabolites in preterm infants

Renwick

Stewart

2021

Acta Paediatrica

View full text Add to dashboard Cite

show abstract

“…Data processing and statistical analysis: For both LC-MS-based [29] and NMRbased [30,31] approaches, an untargeted analytical approach was employed, and, hence, univariate as well as multivariate statistical methods were applied coupled to both unsupervised and supervised methods. Multiple data comparisons were performed as follows to shed light on amifostine's 3D cell anti-angiogenesis metabolome: (a) antiangiogenesis profiling upon deferoxamine stimulation (amifostine_deferoxamine, n = 14 vs. sunitinib_deferoxamine, n = 14), (b) anti-angiogenesis profiling upon VEGF-A stimulation (amifostine_VEGF-A, n = 14 vs. sunitinib_VEGF-A, n = 14), (c) drug-specific anti-angiogenesis profiling (amifostine_deferoxamine_VEGF-A, n = 28 vs. sunitinib_ deferoxamine_VEGF-A, n = 28), and (d) pathway-specific anti-angiogenesis profiling (amifostine_sunitinib_deferoxamine, n = 28 vs. amifostine_sunitinib_ VEGF-A, n = 28).…”

Section: Methodsmentioning

confidence: 99%

Three-Dimensional Cell Metabolomics Deciphers the Anti-Angiogenic Properties of the Radioprotectant Amifostine

Κάτσιλα

Chasapi

Tamayo³

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

Aberrant angiogenesis is a hallmark for cancer and inflammation, a key notion in drug repurposing efforts. To delineate the anti-angiogenic properties of amifostine in a human adult angiogenesis model via 3D cell metabolomics and upon a stimulant-specific manner, a 3D cellular angiogenesis assay that recapitulates cell physiology and drug action was coupled to untargeted metabolomics by liquid chromatography–mass spectrometry and nuclear magnetic resonance spectroscopy. The early events of angiogenesis upon its most prominent stimulants (vascular endothelial growth factor-A or deferoxamine) were addressed by cell sprouting measurements. Data analyses consisted of a series of supervised and unsupervised methods as well as univariate and multivariate approaches to shed light on mechanism-specific inhibitory profiles. The 3D untargeted cell metabolomes were found to grasp the early events of angiogenesis. Evident of an initial and sharp response, the metabolites identified primarily span amino acids, sphingolipids, and nucleotides. Profiles were pathway or stimulant specific. The amifostine inhibition profile was rather similar to that of sunitinib, yet distinct, considering that the latter is a kinase inhibitor. Amifostine inhibited both. The 3D cell metabolomics shed light on the anti-angiogenic effects of amifostine against VEGF-A- and deferoxamine-induced angiogenesis. Amifostine may serve as a dual radioprotective and anti-angiogenic agent in radiotherapy patients.

show abstract

“…With the rapid development and gradual maturation of metabolomics, its application has been implemented in many fields, for example, the study of postnatal metabolic adaptations [103] and neonatal diseases [104,105]. Currently, though, only a few metabolomicsbased studies of ROP have been reported.…”

Section: Retinopathy Of Prematurity (Rop)mentioning

confidence: 99%

Metabolomics in Retinal Diseases: An Update

Cai

et al. 2021

Biology

View full text Add to dashboard Cite

Retinal diseases are a leading cause of visual loss and blindness, affecting a significant proportion of the population worldwide and having a detrimental impact on quality of life, with consequent economic burden. The retina is highly metabolically active, and a number of retinal diseases are associated with metabolic dysfunction. To better understand the pathogenesis underlying such retinopathies, new technology has been developed to elucidate the mechanism behind retinal diseases. Metabolomics is a relatively new “omics” technology, which has developed subsequent to genomics, transcriptomics, and proteomics. This new technology can provide qualitative and quantitative information about low-molecular-weight metabolites (M.W. < 1500 Da) in a given biological system, which shed light on the physiological or pathological state of a cell or tissue sample at a particular time point. In this article we provide an extensive review of the application of metabolomics to retinal diseases, with focus on age-related macular degeneration (AMD), diabetic retinopathy (DR), retinopathy of prematurity (ROP), glaucoma, and retinitis pigmentosa (RP).

show abstract

Metabolic changes in early neonatal life: NMR analysis of the neonatal metabolic profile to monitor postnatal metabolic adaptations

Cited by 11 publications

References 53 publications

Exploring functional metabolites in preterm infants

Exploring functional metabolites in preterm infants

Three-Dimensional Cell Metabolomics Deciphers the Anti-Angiogenic Properties of the Radioprotectant Amifostine

Metabolomics in Retinal Diseases: An Update

Contact Info

Product

Resources

About